Dow Jones 30 Stocks SEC Filings — April 03, 2026

03-04-2026

OSR Holdings, Inc. (OSRH) filed an amendment to its 8-K to provide a corrected binding term sheet dated March 23, 2026, for a global license of VXM01 cancer immunotherapy from its subsidiary Vaximm AG to BCM Europe AG (BCME), OSRH's largest shareholder operating through its fund. OSRH will provide up to $30M development financing to Vaximm, with BCME committing up to $815M in clinical, regulatory, and commercial milestones payable directly to OSRH, and full royalty pass-through after recovery of a 'Negative Milestone Delta' including a 15% preferred return. OSRH retains an equity option to issue up to $15M of common stock to BCME at $10 per share, with a 120-day exclusivity period targeting a definitive agreement by April 30, 2026.

• ·Exclusivity period of 120 days from March 23, 2026, to finalize definitive Global License Agreement, targeting execution by April 30, 2026.
• ·Equity option exercisable at OSRH's discretion no earlier than six months after definitive agreement execution.
• ·Governing law: Switzerland (Canton of Basel); digital asset financing provisions deferred pending regulatory clarity.

03-04-2026

Employees Provident Fund Board filed a 13F-HR report on April 3, 2026, disclosing total holdings of $2,923,831,590 across 45 equity positions as of December 31, 2015. Top holdings include Apple Inc ($252,437,374 for 2,398,227 shares), Wells Fargo & Co New Com ($158,361,389 for 2,913,197 shares), Microsoft Corp Com ($157,300,669 for 2,835,268 shares), Intel Corp Com ($127,463,105 for 3,699,945 shares), and Johnson & Johnson Com ($129,458,427 for 1,260,304 shares). All positions are reported with sole voting authority and no shared or other voting rights.

• ·Report period end date: 12-31-2015
• ·Filing date: 04-03-2026
• ·All 45 holdings reported as SH SOLE (sole voting authority) with 0 shared or other voting authority
• ·SEC file number: 028-26736

03-04-2026

Karman Holdings Inc. reported robust FY2025 revenue growth of 36.6% YoY to $471,500 thousand, fueled by strong performance across all segments including Tactical Missiles and Integrated Defense Systems up 48.5%, with backlog expanding to $801,056 thousand. However, operating margin contracted 2.9 percentage points to 15.5% amid a 92.8% surge in G&A expenses to $85,656 thousand, and cash from operating activities swung to a negative $(22,119) thousand from $26,645 thousand prior year. Net income rose 36.7% to $17,366 thousand, though net income margin remained flat at 3.7%.

• ·Adjusted EBITDA increased to $145,302 thousand in FY2025 from $106,144 thousand in FY2024, with margin slightly up to 30.8%.
• ·Total debt to total capitalization ratio improved to 1.52 from 2.25.
• ·Cash and cash equivalents rose to $33,959 thousand as of Dec 31, 2025 from $11,530 thousand.
• ·GAAP EPS was $0.13 in FY2025 vs $0.08 in FY2024; Adjusted EPS $0.37 vs $0.13.

03-04-2026

Health Catalyst, Inc. entered into a Transition Agreement with former CEO Daniel Burton on March 31, 2026, following his accelerated retirement from the CEO position on February 12, 2026, as previously reported in a Form 8-K on February 18, 2026. Under the agreement, Burton will serve as a strategic advisor until December 31, 2026, receiving an average monthly base salary of $10,000 starting March 1, 2026, in exchange for forfeiting all unvested restricted stock units eligible for vesting after March 2, 2026, and providing a general release of claims. This arrangement facilitates a smooth transition of his prior responsibilities.

• ·Transition Agreement dated March 31, 2026, attached as Exhibit 10.1
• ·Previous Form 8-K filed February 18, 2026, regarding Burton's retirement notice on February 12, 2026
• ·Strategic advisor role ends December 31, 2026

03-04-2026

GE Vernova Inc. (GEV) filed a DEFA14A Definitive Additional Materials proxy statement on April 03, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive proxy details, financial data, or voting matters are included in the provided filing header.

03-04-2026

Valley National Bancorp has filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting of Shareholders, scheduled virtually on May 18, 2026, at 9:00 a.m. ET. Key voting items include the election of 11 director nominees, an advisory vote to approve named executive officer compensation, and ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with the Board recommending 'FOR' on all proposals. Shareholders can vote by May 17, 2026, 11:59 PM ET (or May 13 for 401(k) shares) and request proxy materials by May 4, 2026.

• ·Virtual meeting link: www.virtualshareholdermeeting.com/VLY2026
• ·Voting platform: www.ProxyVote.com
• ·Material request methods: www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com (include control number)
• ·Includes reference to 2025 Annual Report to Shareholders

03-04-2026

Village Farms International, Inc. (VFF) announced a succession plan for Chief Financial Officer Stephen Ruffini, who will transition after 17 years of service to a new role leading M&A activities, remaining as CFO until a permanent replacement is identified. The company highlighted its strong financial position and growth strategy combining organic investments with accretive acquisitions. CEO Michael DeGiglio commended Ruffini's contributions, including NASDAQ uplisting and cannabis expansion.

• ·Hired as CFO in 2009; instrumental in NASDAQ uplisting, debt/equity financings, and cannabis expansion.
• ·Operates EU-GMP certified cannabis facility in Delta, British Columbia, exporting to international medical markets.
• ·Clean Energy division transforms landfill gas into renewable natural gas.

03-04-2026

EVgo Inc. filed a DEFA14A Definitive Additional Materials proxy statement on April 03, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No specific financial or operational details are provided in the filing header.

03-04-2026

Prosperity Bancshares Inc filed an S-4 registration statement for its merger with Stellar, under which each share of Stellar common stock will convert into $11.36 in cash and 0.3803 shares of Prosperity common stock at a fixed exchange ratio. The document emphasizes significant risks, including fluctuations in Prosperity's stock price affecting merger value, substantial transaction and integration costs, potential regulatory delays or conditions, and challenges in realizing synergies or retaining key employees. These factors could lead to adverse effects on Prosperity's operations, stock price, and failure to achieve expected benefits.

• ·Fixed exchange ratio of 0.3803 shares of Prosperity common stock per Stellar common share.
• ·Waiver of prior approval by the Federal Reserve Bank of Dallas obtained on March 17, 2026.
• ·Pending regulatory approvals from Federal Reserve Board or Federal Reserve Bank of Dallas, FDIC, and Texas Department of Banking.
• ·Excludes dissenting shares, treasury shares, and certain shares held by Stellar or Prosperity from conversion.

03-04-2026

National Bank Holdings Corporation (NBHC) filed its definitive proxy statement (DEF 14A) on April 3, 2026, for the 2026 Annual Meeting of Shareholders on May 7, 2026, at Vista Bank in Dallas, TX, where shareholders will vote on electing 10 directors, ratifying KPMG LLP as independent auditors for 2026, an advisory vote to approve named executive officer compensation, and approving the Amended and Restated 2023 Omnibus Incentive Plan. The record date is March 24, 2026, with 44,692,472 shares of Class A common stock outstanding and 952,463 unvested restricted shares entitled to vote. NBHC has engaged Alliance Advisors as proxy solicitor for approximately $35,000 plus reimbursable costs.

• ·Annual Meeting date and time: May 7, 2026 at 8:30 a.m. Central Time
• ·Meeting location: Vista Bank, a division of NBH Bank, 3225 Martin Luther King Jr. Boulevard, Dallas, TX 75210
• ·Record date for voting eligibility: March 24, 2026

03-04-2026

Twin Vee PowerCats Co. received a notification letter from Nasdaq on April 2, 2026, stating it no longer meets the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), based on closing bid prices below $1.00 for 30 consecutive business days from February 18, 2026, to March 31, 2026. Due to a prior 1-for-10 reverse stock split on April 7, 2025, the company is ineligible for a 180-calendar-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A). The company plans to request a hearing by April 9, 2026, to appeal, which would stay delisting pending the Panel's decision, though success is not assured.

• ·Deficiency period: 30 consecutive business days from February 18, 2026, to March 31, 2026
• ·Previous reverse stock split: 1-for-10 effective April 7, 2025
• ·Hearing request deadline: April 9, 2026
• ·Applicable rules: Nasdaq Listing Rule 5550(a)(2) and 5810(c)(3)(A)

03-04-2026

On March 30, 2026, Fidelity National Information Services, Inc. (FIS) was notified that Board Director Mark Benjamin will not stand for re-election at the 2026 annual meeting of shareholders, a decision not due to any disagreement with the Company's operations, policies, or practices. In connection with his departure, the Board approved reducing its size from ten to nine directors, effective immediately following the 2026 Shareholder Meeting. FIS's CEO Stephanie Ferris thanked Mr. Benjamin for his extraordinary contributions and dedication.

• ·Mr. Benjamin’s decision was not due to any disagreement with the Company on any matters relating to the Company’s operations, policies, or practices.

03-04-2026

Ian T. Clark resigned from GoodRx Holdings, Inc.'s Board of Directors, including the Nominating & Governance Committee, effective March 31, 2026, with no disagreement on operations, policies, or practices. To achieve balanced membership across director classes post-resignation, the Board moved Wendy Barnes (CEO, President, and Director) from Class I (term expiring 2027) to Class III (term expiring 2026) via resignation and re-election on April 1-2, 2026, maintaining her uninterrupted service. The Board now consists of three directors in each of Classes I, II, and III.

• ·Filing signed on April 3, 2026

03-04-2026

Inflection Point Acquisition Corp. V, a SPAC, entered into Amendment No. 2 to its promissory note with sponsor Inflection Point Fund I LP on April 2, 2026, increasing the principal amount from $700,000 to $800,000 via a $100,000 advance for working capital. This supports operations ahead of the proposed business combination with GOWell Technology Limited under the October 13, 2025 Business Combination Agreement. No financial performance metrics or declines reported.

• ·Promissory Note originally dated February 12, 2025; Amendment No. 1 on January 7, 2026.
• ·SPAC name change from Maywood Acquisition Corp. on June 26, 2024.
• ·New principal executive offices: 167 Madison Ave, Suite 205 #1017, New York, NY 10016; phone: 212-476-6908.

03-04-2026

NexPoint Diversified Real Estate Trust OP, L.P. (the OP) entered into a Side Letter on April 3, 2026, effective March 30, 2026, purchasing a $962,000 undivided participation interest in the NSP Note from NREF; the NSP Note has a $40 million aggregate principal capacity with $22.7 million outstanding as of April 3, 2026, bears 14% per annum PIK interest, and matures January 16, 2031. The note is secured by a first priority lien on certain income streams and deposit accounts of the co-borrowers, who are affiliates of the Company's Sponsor. The Company owns approximately 53.02% of NSP's common stock and has guaranteed certain NSP obligations.

• ·NSP Note dated January 16, 2026, amended March 25, 2026; interest-only payments.
• ·OP, HFRO, HGLB, NRES, and OSL have right but not obligation to participate pro rata in future advances under NSP Note.
• ·Each Other NSP Note Purchaser and NREF advised or managed by affiliate of Company's Adviser; OSL deemed affiliate through common ownership.

03-04-2026

Drugs Made in America Acquisition Corp II (DMIIU) entered into a Definitive Investment and Sponsor Transition Agreement on March 23, 2026, with Tal Alpha Yezum Vekidum Asakim (2003) LTD for a total financing commitment of $1,400,000 to fund audit, SEC filings, Nasdaq fees, legal costs, and de-SPAC transaction preparation. Of this, $150,000 has been received, $300,000 is due by March 30, 2026, and $950,000 is reserved in escrow; however, the existing sponsor is described as non-performing and subject to legal constraints, necessitating a transition facilitated by the Company. The agreement includes a 4-month timeline to execute an investor-introduced transaction agreement in principle and 6-month exclusivity, with convertible notes at a 35% discount to post-merger market value.

• ·Exclusivity period: 6 months
• ·Timeline: Execute agreement in principle within 4 months
• ·Investor right of first refusal on additional capital beyond $1.4M
• ·No claim on trust account for convertible notes
• ·Maturity of Interim Convertible Note: 9 months from issuance
• ·Governing law: Cayman Islands
• ·Prior agreements superseded: LOI dated March 5, 2026; Addendum No. 1 dated March 9, 2026; Interim Convertible Note dated March 9, 2026; Sponsor Standstill Agreement dated March 18, 2026

03-04-2026

Soluna DV Wind SponsorCo, LLC, an affiliate of Soluna Holdings, Inc., has entered into a Membership Interest Purchase Agreement dated April 1, 2026, to acquire all equity interests in Briscoe Wind Farm, LLC from sellers Briscoe Wind Project Holdings I, LLC, JPM Capital Corporation, and Morgan Stanley Wind LLC. The target company owns an approximately 150-megawatt nameplate capacity wind generation project located in Briscoe County and Floyd County, Texas. No purchase price or financial terms are disclosed in the filing.

• ·Agreement execution date: April 1, 2026
• ·SEC 8-K filing date: April 03, 2026
• ·Project locations: Briscoe County and Floyd County, Texas

03-04-2026

Evernorth Holdings Inc. issued a Form 425 communication on April 3, 2026, regarding its proposed business combination with Armada Acquisition Corp. II (a SPAC), Pathfinder Digital Assets LLC, and related entities, pursuant to a Business Combination Agreement dated October 19, 2025; a registration statement including a preliminary proxy statement/prospectus was filed on March 18, 2026. The filing emphasizes forward-looking benefits such as building the world's leading institutional XRP treasury, executing DeFi yield strategies, and driving XRP adoption, while extensively cautioning on risks including deal failure, regulatory hurdles, XRP price volatility, high redemptions, and operational disruptions. No financial metrics are disclosed, and investors are urged to review SEC filings for full details.

• ·Registration Statement filed with SEC on March 18, 2026 (not yet effective).
• ·Business Combination Agreement dated October 19, 2025.
• ·SEC has not approved the Proposed Transactions; securities unregistered under Securities Act.
• ·Contact: Armada II at 382 NE 191st St., Suite 52895, Miami, Florida 33179-3899 (finance@arringtoncapital.com); Evernorth at 600 Battery St, San Francisco, CA 94111 (finance@evernorth.xyz).

03-04-2026

Hennessy Capital Investment Corp. VII (HVIIU) filed a Form 8-K on April 03, 2026, disclosing entry into a material definitive agreement under Item 1.01, along with Regulation FD disclosure under Item 7.01. Exhibit 99.1 provides further details on the matter. No financial metrics or performance data were included in the provided filing content.

• ·Filing Items: 1.01 (Entry into a Material Definitive Agreement), 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements and Exhibits)
• ·Exhibit: 99.1 attached

03-04-2026

David Chang resigned from the Board of Directors of Battalion Oil Corporation, including his role as Chairman of the Compensation Committee, effective March 31, 2026, and stated he will not stand for re-election. The resignation is explicitly not due to any disagreement with the Company on matters related to operations, policies, or practices.

• ·Resignation letter dated March 30, 2026
• ·Company address: 820 Gessner Road Suite 1100, Houston, Texas 77024

03-04-2026

Getty Images Holdings, Inc. appointed Jeffrey Titterton, a Board member since October 18, 2022, to its Audit Committee on April 3, 2026, determining he meets independence requirements under Rule 10A-3 and NYSE standards. James Quella resigned from the Board and Audit Committee effective April 1, 2026, with no disagreements on company operations, policies, or practices. The Board size remains at eleven directors, with the vacancy to be filled later.

• ·Jeffrey Titterton appointed to Board on October 18, 2022.
• ·James Quella resignation submitted March 31, 2026.
• ·Earliest event reported: March 29, 2026.

03-04-2026

Marwynn Holdings, Inc. filed an S-3 shelf registration statement on April 3, 2026, to register securities for future offerings, incorporating recent 10-K, 10-Q, and 8-K filings. The company, operating an asset-light e-waste reverse supply chain platform called EcoLoopX, highlights risks including partner compliance failures, commodity price fluctuations (copper, lithium, nickel, cobalt), supply shortages, and underdeveloped battery recycling markets, which could materially impact operations. Net proceeds would fund business expansion, potential acquisitions (no targets identified), platform development, working capital, and general corporate purposes.

• ·Fiscal year end: April 30
• ·Business address: 2955 Main Street, Ste 100A, Irvine, CA 92614; Phone: 949-706-9966
• ·Incorporated reports include: 10-K for year ended April 30, 2025 (filed Aug 8, 2025); 10-Qs for periods ended July 31, Oct 31, 2025, and Jan 31, 2026; multiple 8-Ks from Sep 2025 to Apr 2026
• ·SIC: 5141 (Wholesale-Groceries & General Line)
• ·State of incorporation: NV; EIN: 991867981

03-04-2026

Matinas BioPharma Holdings, Inc. received a notice from NYSE American on April 2, 2026, for failing to meet continued listing standards under Sections 1003(a)(i), (ii), and (iii) due to stockholders’ equity of $4.83 million as of December 31, 2025—below the required $2.0M, $4.0M, and $6.0M thresholds amid losses in its five most recent fiscal years. The company plans to submit a compliance plan by May 2, 2026, potentially gaining up to 18 months to cure the deficiency, with no immediate effect on its NYSE American listing or operations. However, compliance is not assured, and rejection of the plan could lead to delisting proceedings.

• ·Company not currently eligible for any exemption under Section 1003(a) of the NYSE American Company Guide.
• ·Shares of common stock (MTNB) continue to be listed and traded on NYSE American pending compliance with other listing requirements.

03-04-2026

NeOnc Technologies Holdings, Inc. reported Q4 2025 financial results showing a significantly widened net loss of $62.1 million ($3.20 per diluted share) compared to $11.9 million ($0.69 per diluted share) in Q4 2024, driven by G&A expenses rising to $4,818k from $1,680k and R&D expenses increasing to $3,638k from $3,045k. Positively, the company completed NEO212 Phase 1 with a recommended Phase 2 dose of 610 mg and early efficacy signals, fully enrolled the NEO100 Phase 2a trial with updated data indicating a 24% radiographic remission rate and 44% six-month progression-free survival, and raised $10 million in PIPE financing anchored by Cinctive Capital Management. Upcoming catalysts include a Type B FDA meeting for NEO212 and preliminary NEO100 Phase 2a data in approximately five months.

• ·NEO212 recommended Phase 2 dose (RP2D) set at 610 mg with early signs of possible anti-tumor activity.
• ·Interim NEO100 Phase 2a data readout expected in approximately five months (August 2026).
• ·NuroMENA executed Master Services Agreement with M42’s IROS.

03-04-2026

Box Hill Private Wealth LLC filed its 13F-HR on April 3, 2026, disclosing $101165816 total portfolio market value as of March 31, 2026, across 66 positions held solely. Largest holdings include Vanguard Index FDS LARGE CAP ETF at 17162280 (57428 shares), iShares TR CORE S&P500 ETF at 14434061 (22097 shares), and Invesco QQQ TR UNIT SER 1 at 6738419 (11675 shares). No prior period data or changes are provided in the filing.

• ·All positions reported as SOLE ownership with 0 shares in other categories
• ·Filer CIK: 0002094120, based in Scottsdale, AZ
• ·Smallest notable position: Booking Holdings Inc (75 shares, value 317147)

03-04-2026

Kinetik Holdings Inc. announced Amendment No. 2 to its Receivables Purchase Agreement (RPA), originally dated April 2, 2024 and previously amended April 1, 2025, effective March 31, 2026, primarily to extend the Scheduled Termination Date. The amendment involves Kinetik Receivables LLC as Seller, Kinetik Holdings LP as Servicer, PNC Bank as Administrative Agent and a Purchaser, with updates to schedules, exhibits, and forms including a new Commitment Increase Request form. No specific financial amounts, changes in commitments, or performance metrics were disclosed.

• ·Amendment includes amendments to Schedule I (Purchasers and Commitments), redesignation of Exhibit B to B-1, addition of new Exhibit B-2 (Form of Commitment Increase Request).
• ·Conditions to effectiveness require documents listed in Exhibit E.
• ·Governed by New York law.

03-04-2026

Crown Reserve Acquisition Corp. I (SPAC) entered into a Business Combination Agreement with Carvix, Inc. on March 30, 2026, involving a domestication to Delaware followed by a merger of a wholly-owned subsidiary into Carvix, with Carvix surviving as a subsidiary; Carvix shareholders will receive 50,000,001 shares of the combined company's common stock at closing plus up to 50,000,100 earnout shares over four years based on escalating EBITDA ($10.38M to $21.84M) and revenue ($276.8M to $436.88M) targets starting 2027. The post-closing board will have five members (four nominated by Carvix, one by Sponsor), with Carvix management continuing to lead. The transaction is subject to customary closing conditions including stockholder approvals, SEC effectiveness, Nasdaq listing, minimum cash after redemptions, and an outside date of September 30, 2026, with potential termination risks.

• ·SPAC founder shares convert one-for-one with Sponsor waiving anti-dilution rights.
• ·Closing conditions include Minimum Cash Amount after redemptions and transaction expenses, HSR waiting period if applicable, and no penny stock issues.
• ·Termination possible prior to September 30, 2026 Outside Date, including for failure to deliver Carvix stockholder consent or audited financials.

03-04-2026

On April 2, 2026, Advanced Biomed Inc. (ADVB) entered into a Share Purchase Agreement to acquire 100% of the equity interest (10,000 ordinary shares) in Acellent Technologies (Hong Kong) Co. Limited, a provider of AI-powered financial verification and audit solutions, from seller Xiaomin Chen for 270,000 shares of ADVB common stock valued at $4.00 per share, totaling $1,080,000. The transaction closing is conditioned upon satisfactory financial and legal due diligence and receipt of all required regulatory approvals. No financial performance metrics or comparisons are provided in the filing.

• ·Target incorporated under laws of Hong Kong
• ·Closing date to be mutually agreed after conditions met
• ·ADVB is an emerging growth company

03-04-2026

Goldman Sachs Private Credit Corp. reported net asset value (NAV) of $9.5 billion and investment portfolio fair value of $16.6 billion as of February 28, 2026, with fund leverage at 0.8x. The company sold unregistered Class I, S, and D shares raising $164.281 million in total consideration. While Class I shares showed positive inception-to-date total return of 9.6% and 1-year return of 7.6%, recent 1-month return was -0.1% and Class S shares had negative short-term returns of -0.2%.

• ·NAV per share as of February 28, 2026: Class I $24.72, Class S $24.72.
• ·February 2026 gross distribution per share: $0.1850 for both Class I and S; net for Class S $0.1708 after $0.0142 fee.
• ·Fund leverage of 0.8x as of February 28, 2026 (average daily borrowings divided by average net assets).
• ·February Distribution declared February 25, 2026, payable on or about April 13, 2026 to stockholders of record as of February 27, 2026.
• ·Class I inception April 6, 2023; Class S inception February 1, 2026.

03-04-2026

VIDA Global Inc., a Delaware-incorporated emerging growth company in the AI sector (SIC 7372), filed an S-1 registration statement on April 2, 2026, for its initial public offering of 3,333,334 shares of Class A common stock at an estimated price of $4.50 to $5.00 per share (midpoint $4.75), with an underwriter over-allotment option for 500,000 additional shares. The company plans to list on NYSE American under the symbol 'VIDA', subject to approval. Post-offering, founders Lyle Pratt (CEO), Brandon Robinson (COO), and Timothy Noah Hayes (Chief Product Officer) will control 86.6% of voting power via Class B shares (86.0% if over-allotment exercised), making it a controlled company.

• ·Incorporated in Delaware (EIN: 88-1438776)
• ·Principal executive offices: 12160 W Parmer Ln, Ste 130-716, Cedar Park, TX 78613; phone: (833) 588-8432
• ·Classified as emerging growth company and smaller reporting company (non-accelerated filer)
• ·Class B common stock: 10 votes per share, convertible to Class A, subject to mandatory conversion events

03-04-2026

Spring Valley Acquisition Corp. III (SVAC) issued a Rule 425 filing disclosing a social media communication from General Fusion Inc. on its progress toward commercializing magnetized target fusion (MTF), including operation of the world-first large-scale Lawson Machine 26 (LM26) demonstration machine and a goal for the first MTF power plant by 2035, amid its proposed business combination under the January 21, 2026 Business Combination Agreement that involves SVAC's continuation to British Columbia, amalgamation with General Fusion, and renaming to General Fusion Group Ltd. The update positions General Fusion as a potential first mover with peer-reviewed results after more than 20 years of development. However, the filing emphasizes extensive forward-looking risks, including failure to complete the merger, commercialization delays, regulatory hurdles, and competition.

• ·Business Combination Agreement dated January 21, 2026
• ·Communication posted April 2, 2026 on LinkedIn and X
• ·Joint Registration Statement on Form F-4 filed with SEC, including preliminary proxy statement
• ·SVAC Final Prospectus dated September 3, 2025
• ·Target first MTF power plant operating by 2035
• ·General Fusion advancing fusion technology for more than 20 years

03-04-2026

Western New England Bancorp, Inc. (WNEB) filed its DEF 14A definitive proxy statement on April 3, 2026, for the 2026 Annual Meeting of Shareholders on May 14, 2026 (record date March 16, 2026), seeking approval for director elections, a non-binding advisory vote on Named Executive Officer compensation, and ratification of Wolf & Company as independent auditors for the fiscal year ending December 31, 2026. The filing includes sections on board composition, corporate governance, executive compensation (with pay-versus-performance data for 2023-2025), director compensation, and security ownership, but no specific financial performance metrics or period-over-period changes are detailed in the provided content. As of the record date, 20,258,872 shares of common stock were outstanding.

• ·Annual Meeting location: Sheraton Springfield Monarch Place Hotel, One Monarch Place, Springfield, Massachusetts 01114 at 10:00 A.M. Eastern Daylight Time.
• ·Proxy materials available at wneb.q4ir.com/financials/proxy-materials and web.viewproxy.com/WNEB/2026.
• ·Shareholder proposals for 2027 Annual Meeting must be submitted by December 4, 2026.

03-04-2026

Enviri Corporation entered into definitive agreements on November 20, 2025, with Veolia Environnement S.A. to sell its Clean Earth business for $3.04 billion in cash, subject to adjustments, involving a holding company merger, separation, spin-off of the remaining Harsco Environmental and Harsco Rail businesses as New Enviri, and subsequent merger of the Clean Earth entity with Veolia. Shareholders of record will receive cash consideration of not less than $14.50 nor more than $16.50 per share upon closing. The Enviri Board unanimously approved the transactions and recommends voting 'FOR' the Transaction Proposal, advisory executive compensation, and Adjournment Proposal at the virtual Special Meeting on May 4, 2026.

• ·Special Meeting: May 4, 2026, at 9:00 AM Eastern Time, virtual via https://meetnow.global/MRZPGPM
• ·Transaction Proposal requires majority of outstanding Enviri common stock entitled to vote
• ·Non-Binding Merger-Related Executive Compensation Proposal and Adjournment Proposal each require majority of shares present and entitled to vote
• ·Per share merger consideration to be determined and announced by Enviri Board no later than five business days prior to Closing

03-04-2026

Bank of America highlighted robust 2025 performance in this DEFA14A proxy supplement, reporting Net Income of $30.5B (up 13% YoY), Revenue of $113.1B (up 7% YoY), diluted EPS up 19%, and ~250 bps of operating leverage, with strong growth across segments including Consumer Banking's ~680,000 net new checking accounts and $599B investment assets (up 16% YoY), Global Wealth & Investment Management's $4.8T client balances (up 12% YoY), and record Global Markets sales and trading revenue. The materials seek shareholder approval for 12 director nominees, Say on Pay vote, and ratification of PricewaterhouseCoopers LLP as auditor, while recommending votes against two shareholder proposals on independent board chair and animal welfare risk reporting. TSR reached 28% in 2025 following 34% in 2024.

• ·28 consecutive quarters of net new checking account growth in Consumer Banking.
• ·15 consecutive quarters of YoY sales and trading revenue growth in Global Markets.
• ·21 consecutive quarters of average loan growth in Global Markets.
• ·Global #3 investment banking fee ranking (Dealogic as of Dec 31, 2025).
• ·One of only 4 U.S. companies with over $15.0B Net Income in each of the last 11 years.
• ·Ranked #2 vs. primary competitors on 2025 Net Income, Revenue, and Market Capitalization.
• ·Shareholder outreach to 74 institutional shareholders representing ~45% of institutionally held shares.

03-04-2026

CitroTech Inc. entered into a Transition Agreement with Stephen Conboy, its former Chief Technology Officer, effective March 31, 2026, transitioning him to an outside advisor role for a 90-day period ending June 30, 2026, with monthly payments of $10,000 and product advances up to $200,000. Post-transition, Conboy gains exclusive sales rights for specified products in a Tahoe-area territory subject to minimum gross sales thresholds of $500,000 in 2026 and $2,000,000 thereafter, along with equity provisions triggered by $10,000,000 financing or revenue milestones. His resignation from the CTO position was not due to any disagreements with the company.

• ·Transition Period: March 31, 2026 to June 30, 2026 (90 days)
• ·Exclusive sales territory: near North Lake Tahoe, South Lake Tahoe, and Truckee, California
• ·Agreement includes broad release of claims, confidentiality, non-disclosure, restrictive covenants, and non-disparagement provisions
• ·Post-transition affiliate agreement to be negotiated for commissions on net sales in defined territory

03-04-2026

KORU Medical Systems, Inc. entered into Amendment No. 3 to its Loan and Security Agreement with HSBC Ventures USA Inc., effective March 30, 2026, extending the Revolving Line Maturity Date to March 30, 2028, Term Loan Maturity Date to December 1, 2029, and Draw Period End Date to June 30, 2027, with potential further extensions upon achieving the EBITDA Milestone Event of positive Adjusted EBITDA for two consecutive fiscal quarters by June 30, 2027. Interest rates were adjusted to the greater of Prime Rate (or Prime minus 0.50% for Term Loans) or 5.50%, and the financial covenant shifted to Remaining Months Liquidity greater than 12, replacing the prior Adjusted Quick Ratio, while requiring at least $5,000,000 in unrestricted cash with the Bank. No declines or flat metrics are present in this amendment, which provides extended financing flexibility conditional on performance.

• ·Eligible Foreign Accounts limited to Account Debtors in Approved Countries: Canada, France, Germany, Italy, Japan, United Kingdom.
• ·Term Loan Amortization Date: July 1, 2027, extendable to January 1, 2028 upon EBITDA Milestone Event.
• ·Repayment Schedule: 30 months, reducible to 24 months upon EBITDA Milestone Event.
• ·Financial covenant tested monthly after Testing Event (initial Advance), with exception if trailing three-month average Adjusted EBITDA is positive.

03-04-2026

Harmony Biosciences Holdings, Inc. (HRMY) filed definitive additional proxy materials (DEFA14A) on April 3, 2026, for its 2026 Annual Meeting of Stockholders scheduled for May 14, 2026, at 1:00 p.m. ET virtually. Shareholders are to vote on: (1) election of four Class III directors (Geno J. Germano, Troy Ignelzi, Ron Philip, Andreas Wicki, Ph.D.) to serve until the 2029 annual meeting; (2) ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026; and (3) a non-binding advisory vote on named executive officer compensation.

• ·Voting deadline: May 13, 2026, 11:59 p.m. ET
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/HRMY2026
• ·Proxy materials request deadline: April 30, 2026
• ·Control numbers referenced: V89931-P48489, V89932-P48489

03-04-2026

Live Oak Acquisition Corp. V (LOKVU) filed an S-4 registration statement detailing a proposed business combination with Teamshares, assuming completion of a $126.5 million PIPE investment and various redemption scenarios up to $239.0 million for 23,000,000 public shares at approximately $10.39 per share from the Trust Account as of December 31, 2025. Transaction costs are expected at $5.16 million, with potential dilution to net tangible book value from deferred sponsor shares and high redemptions that could reduce trust proceeds significantly. Post-merger, the combined company will rely entirely on Teamshares for operations and cash flows, exposing it to substantial risks including no direct operations and dependency on distributions.

• ·Filing date: April 03, 2026
• ·Trust Account based on funds as of December 31, 2025
• ·No specified maximum redemption threshold, allowing completion despite substantial shareholder redemptions
• ·Sponsor and affiliates may purchase shares/warrants privately, potentially influencing vote and reducing public float

03-04-2026

Eagle Bancorp, Inc. (EGBN) filed a DEFA14A Definitive Additional Proxy Materials on April 03, 2026, as part of Schedule 14A under Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and appears to be a notice and access card (based on filename). No specific financial data, proposals, or other substantive details are provided in the extracted content.